GRI Bio, Inc. (GRI )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol GRI
- Company GRI Bio, Inc.
- Price $1.84
- Changes Percentage 26.9
- Change 0.39
- Day Low $1.51
- Day High $2.11
- Year High $106.08
- Year Low $1.1
- Market Cap $1,338,339
- Price Avg 50 EMA (D) $5.31
- Price Avg 200 EMA (D) $10.76
- Exchange NASDAQ
- Volume 1,261,131
- Average Volume 346,536
- Open $1.51
- Previous Close $1.45
- EPS -55.19
- PE -0.03
- Earnings Announcement 2025-05-12 12:30:00
- Shares Outstanding $727,358
Company brief: GRI BIO, INC. (GRI )
- Healthcare
- Biotechnology
- Dr. W. Marc Hertz Ph.D.
- https://www.gribio.com
- US
- N/A
- 02-10-2021
- US3622AW2059
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.